Emma L Weizenbaum, Stephanie Hsieh, Cassidy Molinare, Daniel Soberanes, Caitlyn Christiano, Andrea M Román Viera, Juliana A U Anzai, Stephanie Moreno, Emily C Campbell, Hyun-Sik Yang, Gad A Marshall, Reisa A Sperling, Kathryn V Papp, Rebecca E Amariglio
{"title":"Validation of the multi-day Boston remote assessment of neurocognitive health (BRANCH) among cognitively impaired & unimpaired older adults.","authors":"Emma L Weizenbaum, Stephanie Hsieh, Cassidy Molinare, Daniel Soberanes, Caitlyn Christiano, Andrea M Román Viera, Juliana A U Anzai, Stephanie Moreno, Emily C Campbell, Hyun-Sik Yang, Gad A Marshall, Reisa A Sperling, Kathryn V Papp, Rebecca E Amariglio","doi":"10.1016/j.tjpad.2025.100057","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The multi-day Boston Remote Assessment of Neurocognitive Health (BRANCH) is a remote, web-based assessment designed to capture the earliest cognitive changes in the preclinical stage of Alzheimer's disease (AD). It has been validated in unimpaired older adults, but as individuals progress on the AD continuum, assessments need to remain feasible and valid at different clinical stages. The focus of this study was to assess feasibility and validity of multi-day BRANCH in participants with and without cognitive impairment.</p><p><strong>Methods: </strong>For seven days participants completed the BRANCH paradigm to capture a muti-day learning curve score. Participants also completed the mini-mental-status-exam (MMSE) and the Quick Dementia Rating Scale (QDRS). The primary cohort included 81 older adults: 38 with cognitive impairment (CI) and 43 cognitively-unimpaired (CU). A complementary replication cohort included 16 participants with consensus-defined mild cognitive impairment (MCI) and 47 demographically-matched cognitively unimpaired participants.</p><p><strong>Results: </strong>Multi-day BRANCH was feasibile with 92 % or participants completing all seven days of testing. More CI than CU reported nervousness and found tasks slightly less enjoyable on Day 1, but ratings increased at a similar rate in both groups. Convergent validity was confirmed by a positive association between BRANCH and total MMSE and QDRS scores. There was a large effect size of group status on BRANCH (CI vs. CU; Cohen's d = 0.83) and per logistic regression, BRANCH significantly predicted group status (β = -1.49, p < 0.001); even more so between MCI and CU in the replication cohort.</p><p><strong>Conclusions: </strong>Findings suggest that a remotely administered web-based assessment of multi-day learning is feasible and valid in participants with and without cognitive impairment.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":" ","pages":"100057"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tjpad.2025.100057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The multi-day Boston Remote Assessment of Neurocognitive Health (BRANCH) is a remote, web-based assessment designed to capture the earliest cognitive changes in the preclinical stage of Alzheimer's disease (AD). It has been validated in unimpaired older adults, but as individuals progress on the AD continuum, assessments need to remain feasible and valid at different clinical stages. The focus of this study was to assess feasibility and validity of multi-day BRANCH in participants with and without cognitive impairment.
Methods: For seven days participants completed the BRANCH paradigm to capture a muti-day learning curve score. Participants also completed the mini-mental-status-exam (MMSE) and the Quick Dementia Rating Scale (QDRS). The primary cohort included 81 older adults: 38 with cognitive impairment (CI) and 43 cognitively-unimpaired (CU). A complementary replication cohort included 16 participants with consensus-defined mild cognitive impairment (MCI) and 47 demographically-matched cognitively unimpaired participants.
Results: Multi-day BRANCH was feasibile with 92 % or participants completing all seven days of testing. More CI than CU reported nervousness and found tasks slightly less enjoyable on Day 1, but ratings increased at a similar rate in both groups. Convergent validity was confirmed by a positive association between BRANCH and total MMSE and QDRS scores. There was a large effect size of group status on BRANCH (CI vs. CU; Cohen's d = 0.83) and per logistic regression, BRANCH significantly predicted group status (β = -1.49, p < 0.001); even more so between MCI and CU in the replication cohort.
Conclusions: Findings suggest that a remotely administered web-based assessment of multi-day learning is feasible and valid in participants with and without cognitive impairment.
背景:为期多天的波士顿神经认知健康远程评估(BRANCH)是一项基于网络的远程评估,旨在捕捉阿尔茨海默病(AD)临床前阶段最早的认知变化。它已在未受损的老年人中得到验证,但随着个体在AD连续体上的进展,评估需要在不同的临床阶段保持可行性和有效性。本研究的重点是评估多日BRANCH在有和无认知障碍参与者中的可行性和有效性。方法:参与者在七天内完成BRANCH范式,以获取多日学习曲线得分。参与者还完成了小型精神状态检查(MMSE)和快速痴呆评定量表(QDRS)。主要队列包括81名老年人:38名有认知障碍(CI), 43名无认知障碍(CU)。补充复制队列包括16名一致定义为轻度认知障碍(MCI)的参与者和47名人口统计学匹配的认知未受损参与者。结果:多天BRANCH是可行的,92%的参与者完成了所有7天的测试。CI比CU更多的人报告紧张,并且在第一天发现任务稍微不那么愉快,但两组的评分增长速度相似。BRANCH与总MMSE和QDRS得分之间的正相关证实了收敛效度。分组状态对BRANCH的效应量很大(CI vs. CU;Cohen’s d = 0.83),根据logistic回归,BRANCH显著预测组状态(β = -1.49, p < 0.001);在复制队列中MCI和CU之间更是如此。结论:研究结果表明,对有或无认知障碍的参与者进行远程管理的基于网络的多日学习评估是可行和有效的。
期刊介绍:
The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.